Genome Editing is a group of technologies that enables gene professionals to change an organism's DNA. These technologies enable genetic material to be added, altered or removed at particular location in the gene. Genome editing also referred as the gene editing. Genome editing has indicated a good potential for the treatment of genetic disorders, infectious disease and cancer. Genome editing is one of the great interests in the prevention and treatment of human diseases including understanding diseases using animal and cells models, to determine predicted approach is safe and effective for use in human.
Gene editing also being explored in research on a wide range of diseases, including single-gene disorders like hemophilia, cystic fibrosis and sickle cell diseases among others. It is capable to treatment and prevention of more critical disease including cancer, mental illness, heart disease, and human immunodeficiency virus (HIV) infection. The first genome editing advancements were developed in the last part of the 1900s. As recently, another genome editing tool called CRISPR, developed in 2009, has made it simpler than any time in recent memory to alter DNA. CRISPR is easier, quicker, less expensive, and more precise than older genome editing strategies. Numerous researchers who perform genome editing presently using CRISPR.
Headquarters: BAARERSTRASSE 14, Zug, Zug, 6300, Switzerland
CRISPR Therapeutics AG is Switzerland - American Biotechnology Company. CRISPR Therapeutics agents focus on the development of deformation medications using an exclusive CRISPR / CAS9 platform. CRISPR / CAS9 is an innovative technology that allows accurate and indefinite modifications of genomic DNA. The Vision of Therapeutics Crispr is to treat a serious human disease at the molecular level using CrispasPas9. CRISPR Therapeutics had nearly 304 employees and had $289 Million in revenue.
Headquarters : 1710 Commercial Park, Coralville, Iowa, 52241, United States
Integrated DNA Technologies, Inc. (IDT) is a US-based company and supplier of custom nucleic acids serving the fields of academic research, biotechnology, clinical diagnostics, and pharmaceutical development. IDT's core business is the production of custom DNA and RNA oligonucleotides (oligos) for research applications Integrated DNA technology sells short strands of DNA called oligonucleotides IDT has developed proprietary technologies for genomic applications such as next-generation sequencing, CRISPR genome editing, qPCR, and RNA interference. Through its GMP services, IDT manufactures products used in diagnostic tests for many forms of cancer and most genetic and infectious diseases. Integrated DNA Technologies had nearly 1,400 employees and had $268 Million in revenue.
Headquarters: 7000 Marina Blvd, Brisbane, California, 94005, United States
Sangamo Therapeutics, Inc. (formerly Sangamo Biosciences, Inc.) is an American Biotech company that translates groundbreaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company's product system includes hemophilia, central nervous system, HIV, lysosomal storage disorders and hemoglobinopathy. Sangamo Therapeutics had nearly 354 employees and had $102 million in revenue.
Headquarters : 240 County Rd, Ipswich, Massachusetts, 01938, United States
New England Biolabs (NEB) US-based company that manufactures and supplies recombinant and native enzyme reagents for life science research and provides solutions that support genome editing, synthesis of learning of biology and next-generation sequencing. NEB also offers free access to research tools such as REBASE, InBASE and Polbase. The company offers limited endonucleases for DNA degradation; PCR, polymerase and amplification technology for PCR applications; DNA modification enzymes and cloning technology; reagents for the preparation of DNA and RNA samples; DNA, RNA and protein markers and scales for electrophoresis applications; reagents for RNA research; and gene expression tools for gene transfer from DNA, RNA and cell line proteins. New England Biolabs had nearly 500 employees and had $96 Million in revenue
Headquarters: 8100 Cambridge Research Park, Waterbeach, Cambridgeshire, CB25 9TL, United Kingdom
Horizon Discovery Group is a UK-based Gene Editing company that designs and manufactures genetically modified cells, then applies them to research and clinical applications to improve human health. The company's gene editing and preparation platform, capable of modifying almost any DNA sequence or RNA copy, has generated a portfolio of more than 1,000,000 cell products and reagents that help scientists Research summarizes the genetic and protein abnormalities found in diseases such as cancer. The Horizon solution allows virtually any gene to be altered or adjusted for its function in human and other mammalian cell lines. Horizon Discovery Limited had nearly 416 employees and $75 million in revenue.
Headquarters : 9620 Medical Center Dr, Ste 200, Rockville, Maryland, 20850, United States
OriGene Technologies is a US-based company founded as a research tools company focused on creating the largest commercial collection of complete human cDNAs. It strives to fulfill its mission of providing everything a researcher needs for genetic research. By licensing and selling research materials, including genes, proteins, and research tools, it enables important biological research. OriGene Technologies uses a high-throughput, genomic scale approach to develop products for pharmaceutical, biotechnology, and academic research. OriGene offers unique gene expression products, such as the TissueScan cancer tissue qPCR array and tissue biomembrane for biomarker detection and validation. New England Biolabs had nearly 137 employees and had $68 Million in revenue.
Headquarters : 3565 Haven Avenue, Suite 1, Menlo Park, California, 94025, United States
Synthego is a US-based Genomics Engineering Innovation Company. The company enables accelerated research and development in the life sciences with the aim of improving human health. The company leverages machine learning, automation, and gene editing to build science platforms at scale. With its background in the engineering disciplines, the company's fullstack platform vertically integrates proprietary hardware, software, bioinformats, chemistry, and molecular biology to advance both basic research and therapeutic development programs. Synthego had nearly 250 employees and had $48 Million in revenue
Headquarters: Medawar 1, Robert Robinson Avenue, Oxford, Oxfordshire, OX4 4GA, United Kingdom
OXGENE, a WuXi Advanced Therapies (WuXi ATU) company, based in Oxford, UK, provides cell and gene therapy pioneers worldwide with automation platforms and technologies and service solutions including they need to stay ahead in the race for breakthrough therapies. The Company's technology helps pioneers advance their CART, CRISPR, capsid or promoter discovery programs. bioproduction solutions further accelerate the development and scalable production of treatments based on lentiviral, AAV or adenoviral vectors. OXGENEhad nearly 95 employees and had $19 Million in revenue.
Headquarters : 9430 Ave, Key West Ste 105, Rockville, Maryland, 20850, United States
Vigene Biosciences is an award-winning, US-based global leader in the development and production of plasmid and viral vectors. Vigene develops gene delivery technologies with a mission to advance biomedical research and make gene therapy affordable. It offers both AAV, research-grade lentiviral and adenovirus products, and cGMP as well as personalized services. Some of its product offerings include genome-wide human ORF cDNA on adenoviral or lentiviral vectors, AAV shRNA constructs, pre-made control GFP viruses, AAV biosensors developed in collaboration collaboration of the Janelia Research Facility, the alphasynuclein AAV vector was developed in collaboration with the Michael J Fox Foundation and many others. Vigene Biosciences had nearly 108 employees and had $16 Million in revenue.
Headquarters : 302 E Pettigrew St, Ste A-100, Durham, North Carolina, 27701, United States
Precision BioSciences is a US-based biotech company that aims to improve lives through next-generation gene editing technology, ARCUS. Precision BioSciences' mission is to transform the world's most powerful genome editing technology in life sciences essential products. Precision's proprietary ARCUS genome editing technology enables the production of highly specific nucleases that can insert, remove, and modify DNA at virtually any site in a complex genome. Precision Biosciences had nearly 199 employees and had $10 Million in revenue.
Key Benefits for Global Genome Editing Market Report–